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POST MARKETING SURVEILLANCE OF VORICONAZOLE (VORI) USE IN
HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS AT A
SINGLE ACADEMIC INSTITUTION
Leather, H.L.1, Pazzalia, A.2, Corey, M.1, Wingard, J.R.2 1. Shands at
the University of Florida, Gainesville, FL; 2. College of Medicine,
Division of Heme-Onc, University of Florida, Gainesville, FL.
VORI, a second generation triazole, was approved by the FDA
on 5/28/02. One of the major concerns with VORI is its adverse
drug reaction proﬁle and the numerous drug interactions that are
likely to occur in pts receiving polypharmacy. We retrospectively
evaluated all pts receiving VORI admitted to the HSCT program
from 08/02 - 10/20/03. Of 45 evaluable pts, 11% underwent
autologous HSCT, 22% allogeneic HSCT, 20% MUD HSCT,
7% UCB, and 40% received chemotherapy for leukemia or lym-
phoma. Twenty pts (44.5%) received steroids prior to VORI (7
received 1 mg/kg/d; 5 x 1 mg/kg/d; 1 x 1.5 mg/kg/d and 7 x 2
mg/kg/d). VORI was was used empirically in 76% of cases, pro-
phylactically in 9%, and was used to treat documented fungal
disease in 15%. According to the EORTC/MSG deﬁnitions for
IFI, 29% of pts had a proven infection, 56% had a possible IFI, and
6% did not meet established criteria. VORI was used as ﬁrst-line
therapy in 82% pts. Of the documented infections treated, there
were 2 Aspergillus non-fumigatus, 2 A.fumigatus, 1 A. ﬂavus, 2
Fusarium spp., 1 Basidiomycete, 1 Curvularia spp., 1 dematiaceous
mold, 1 Candida albicans, and 1 polyfungal infection (A. fumigatus
and Penicillium spp.). CR’s were seen in 15% cases, PR’s in 46%
cases and PD occurred in 38% cases. Combination therapy was
used in 20% of pts (5 VORI  caspofungin; 2 VORI  ABLC, 1
VORI  cAmB, 1 VORI  AmBisome, 1 VORI  AmBisome 
caspofungin).
Mean duration of voriconazole was 27 days (range 2 - 130).
Loading doses were administered in 87% pts. VORI was admin-
istered PO in 76% pts and 22% IV, 2% PO  IV. Interacting
medications were prescribed in 87% pts. The interaction of great-
est concern is between calcineurin inhibitors (CyA and FK506) and
VORI. Calcineurin inhibitors were prescribed to 20 pts (44%). Of
these, 13 (65%) were succesfully dose adjusted to achieve thera-
peutic serum concentrations, 5 (25%) had dose modiﬁcations, but
resulted in supratherapeutic concentrations, and 2 pts did not have
the required dose modiﬁcation made (1 resulting in toxicity). Ad-
verse events were seen in 15 pts (3 visual;1 AMS; 11 abnormal
LFT’s). Of pts with normal BL LFT’s, 15% had increases in
bilirubin, 28% in AST, 15% in ALT, and 28% in alk phosphatase.
Among the documented infections treated, VORI resulted in
similar response rates to published studies. It is effective, and while
there are numerous drug interactions, if managed appropriately,
this is a safe agent to use in this high-risk population.
296
PILOT STUDY OF ORAL DOLASETRON AND DEXAMETHASONE FOR THE
CONTROL OF NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE
CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANS-
PLANTATION
Fancher, K.M.1, Tsai, K.-T.2, Tate, C.A.1, Fields, K.K.1 1. H. Lee
Mofﬁtt Cancer Center & Research Institute, Tampa, FL; 2. Aventis
Pharmaceuticals, Bridgewater, NJ.
The efﬁcacy of oral dolasetron and dexamethasone in patients
receiving high-dose chemotherapy followed by autologous stem
cell transplantation was evaluated. In an open-label, non-compar-
ative study, 43 patients who received conditioning with high-dose
chemotherapy were given oral dolasetron 100 mg daily (one hour
prior to each dose of chemotherapy) and on each day of rest.
Patients also received oral dexamethasone 10 mg twice daily, start-
ing one hour prior to the ﬁrst dose of chemotherapy and continu-
ing through each day of rest. Patients were permitted to use
prochlorperazine, lorazepam, haloperidol, and/or droperidol on an
as-needed basis at their request. Objective data such as number of
emetic episodes and quantity of rescue medications used during the
study period were recorded. Subjective rankings of nausea and
vomiting were assessed using a 100 mm visual analogue scale every
12 hours throughout the study period. The overall response rate
was 85% (67.5% complete response, 17.5% partial response). The
mean number of emetic episodes was 0.2 on each day of the
study, and a mean of 2 rescue medications were used each day.
Mean visual analogue scores did not exceed 25 mm at any time
during the study. No unexplained laboratory or clinical parameters
were noted. The data suggest that the combination of oral dolas-
etron and oral dexamethasone is safe and effective in controlling
nausea and vomiting in patients undergoing high-dose chemother-
apy followed by autologous stem cell transplantation.
297
TWICE DAILY CEFEPIME FOR FEBRILE NEUTROPENIA FOLLOWING
AUTOLOGOUS STEM CELL TRANSPLANTATION
Gunderson, H.D., Miller, D.D., Wolf, R.C. Department of Pharmacy,
Mayo Clinic, Rochester, MN.
Neutropenic patients following high-dose chemoradiotherapy
and autologous hematopoietic stem cell transplantation (HSCT)
are predisposed to potentially life-threatening infections. Cefepime
two grams every eight hours is an established monotherapy regi-
men. Cefepime two grams twice daily is efﬁcacious for numerous
other indications and would be a convenient alternative for HSCT
inpatients and outpatients.
Following IRB-approval, a retrospective, single institution co-
hort study of 171 autologous HSCT patients was conducted. From
1998 to 2000, 88 females and 83 males received cefepime twice
daily for neutropenic fever. Median age was 54 years (range, 20-76)
and underlying diagnoses included lymphoma (n  67), myeloma
(n 48), solid tumor (n 25), amyloidosis (n 17), leukemia (n
12), and scleroderma (n  2). Cefepime was initiated between day
2 and 17 (median, 6) following HSCT. Duration of therapy
ranged from 1 to 20 days (median, 6).
Immunocompromised Host Society outcome criteria were
strictly applied. A failure was ascribed if any antimicrobial was
added secondary to persistent fever or culture results within 72
hours of initiation. Forty-two patients (24.5%) successfully eradi-
cated neutropenic fever or microbiologically documented infec-
tion. Seventy patients (40.9%) developed positive blood cultures;
12 of 70 (17.1%) were polymicrobial. Forty-one patients (58.6% of
all bacteremias) were coagulase negative Staphylococci (SCN)
while gram-negative bacilli occurred in 18 (25.7%). Twelve pa-
tients (7%) received empiric antifungal therapy and one patient
died (0.6%) secondary to infection (aspergillosis). Time to defer-
vescence ranged from 1 to 20 days (median, 5) while neutropenia
lasted 4 to 106 days (median, 9). Forty-seven patients (27.5%)
initially responded, but had modiﬁcation to their regimen when
secondary infections arose [e.g. Clostridium difﬁcile (n  15)], or
adverse effects developed [e.g. rash (n  22)]. Overall, eighty-nine
patients (52%) initially responded. Eighty-two patients (48%) were
classiﬁed as failures. Frequent SCN bacteremias and infections
outside the spectrum may partially explain the failure rate. Twice
daily cefepime is convenient, effective therapy, but frequently re-
quires modiﬁcation.
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